阿姆斯特丹 MS 队列中多发性硬化症成年患者中的 SARS-CoV-2 抗体。
SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort.
机构信息
Department of Neurology, Amsterdam Neuroscience, Amsterdam MS Center, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, the Netherlands.
Department of Immunopathology, Sanquin Research, Amsterdam, the Netherlands.
出版信息
JAMA Neurol. 2021 Jul 1;78(7):880-882. doi: 10.1001/jamaneurol.2021.1364.
Abstract
This cohort study assesses a group of patients with multiple sclerosis in Amsterdam, the Netherlands, for SARS-CoV-2 antibodies to quantify asymptomatic infections and immunological response to COVID-19.
摘要
本队列研究评估了荷兰阿姆斯特丹的一组多发性硬化症患者的 SARS-CoV-2 抗体，以量化无症状感染，并了解针对 COVID-19 的免疫反应。
相似文献
1
SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort.阿姆斯特丹 MS 队列中多发性硬化症成年患者中的 SARS-CoV-2 抗体。
JAMA Neurol. 2021 Jul 1;78(7):880-882. doi: 10.1001/jamaneurol.2021.1364.
2
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.COVID-19 恢复期多发性硬化症患者对 SARS-CoV-2 的体液和细胞反应。
Neurol Neuroimmunol Neuroinflamm. 2022 Feb 1;9(2). doi: 10.1212/NXI.0000000000001143. Print 2022 Mar.
3
Encephalopathy associated with COVID-19 in a patient with multiple sclerosis.COVID-19 相关脑炎合并多发性硬化症患者
J Neurovirol. 2020 Dec;26(6):973-975. doi: 10.1007/s13365-020-00921-5. Epub 2020 Oct 28.
4
Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.新型冠状病毒抗体阳性多发性硬化症患者中疾病修正治疗的安全性。
Mult Scler Relat Disord. 2021 Apr;49:102754. doi: 10.1016/j.msard.2021.102754. Epub 2021 Jan 13.
5
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.用芬戈莫德和特立氟胺治疗的多发性硬化症患者中新冠病毒血清转化及病情进展缓慢情况
J Neurol Sci. 2020 Sep 15;416:117011. doi: 10.1016/j.jns.2020.117011. Epub 2020 Jul 4.
6
COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies.7 例接受抗 CD20 治疗的多发性硬化症患者合并 COVID-19。
Mult Scler Relat Disord. 2020 Sep;44:102306. doi: 10.1016/j.msard.2020.102306. Epub 2020 Jun 15.
7
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report.奥瑞珠单抗治疗的 MS 患者对 SARS-CoV-2 的血清学应答是否得到保留？一例报告。
Mult Scler Relat Disord. 2020 Sep;44:102323. doi: 10.1016/j.msard.2020.102323. Epub 2020 Jun 22.
8
Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.奥法妥木单抗治疗复发性多发性硬化症患者中 SARS-CoV-2 免疫球蛋白 M 和 G 抗体的产生。
Mult Scler Relat Disord. 2021 Apr;49:102777. doi: 10.1016/j.msard.2021.102777. Epub 2021 Jan 19.
9
Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients.评估多发性硬化症患者队列中与 COVID-19 相关的急性呼吸道疾病易感性。
Mult Scler Relat Disord. 2020 Nov;46:102453. doi: 10.1016/j.msard.2020.102453. Epub 2020 Aug 19.
10
Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays.新型冠状病毒中和抗体与商业血清学检测的相关性。
Clin Chem. 2020 Dec 1;66(12):1538-1547. doi: 10.1093/clinchem/hvaa211.
引用本文的文献
1
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy.血液系统疾病患者和细胞治疗接受者的奥密克戎SARS-CoV-2感染管理及结局
Front Oncol. 2024 Jun 19;14:1389345. doi: 10.3389/fonc.2024.1389345. eCollection 2024.
2
Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.多发性硬化症患者在接受疾病修正治疗后的突破性 COVID-19 风险。
J Neurol. 2023 Oct;270(10):4632-4639. doi: 10.1007/s00415-023-11935-4. Epub 2023 Aug 17.
3
COVID-19: The Course, Vaccination and Immune Response in People with Multiple Sclerosis: Systematic Review.COVID-19：多发性硬化症患者的病程、疫苗接种和免疫反应：系统评价。
Int J Mol Sci. 2023 May 25;24(11):9231. doi: 10.3390/ijms24119231.
4
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.原发性 SARS-CoV-2 感染在免疫介导的炎症性疾病患者中的情况：长期体液免疫反应及其对疾病活动的影响。
BMC Infect Dis. 2023 May 17;23(1):332. doi: 10.1186/s12879-023-08298-6.
5
Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates.恢复期血浆治疗曾接受 B 细胞耗竭单克隆抗体治疗的 COVID-19 患者与降低再入院率相关。
Viruses. 2023 Mar 15;15(3):756. doi: 10.3390/v15030756.
6
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.鞘氨醇-1-磷酸受体调节剂对 COVID-19 和 SARS-CoV-2 疫苗接种的影响。
Mult Scler Relat Disord. 2023 Jan;69:104425. doi: 10.1016/j.msard.2022.104425. Epub 2022 Nov 22.
7
Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination.接种疫苗前有或无SARS-CoV-2感染的多发性硬化症患者的SARS-CoV-2纵向体液反应。
Front Neurol. 2022 Nov 10;13:1032830. doi: 10.3389/fneur.2022.1032830. eCollection 2022.
8
Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients with Multiple Sclerosis.奥瑞珠单抗浓度是多发性硬化症患者对 SARS-CoV-2 疫苗接种反应的良好预测指标。
Ann Neurol. 2023 Jan;93(1):103-108. doi: 10.1002/ana.26534. Epub 2022 Nov 2.
9
Risk and severity of SARS-CoV-2 reinfection among patients with multiple sclerosis vs. the general population: a population-based study.多发性硬化症患者与普通人群 SARS-CoV-2 再感染的风险和严重程度：一项基于人群的研究。
BMC Neurol. 2022 Oct 8;22(1):379. doi: 10.1186/s12883-022-02907-8.
10
Skeletal Muscle and COVID-19: The Potential Involvement of Bioactive Sphingolipids.骨骼肌与2019冠状病毒病：生物活性鞘脂的潜在作用
Biomedicines. 2022 May 4;10(5):1068. doi: 10.3390/biomedicines10051068.
Zotero 插件